Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study. Issue 1 (27th October 2021)

• Record Type: Journal Article
• Authors: Trucco, Federica; Ridout, Deborah; Domingos, Joana; Maresh, Kate; Chesshyre, Mary; Munot, Pinki; Sarkozy, Anna; Robb, Stephanie; Quinlivan, Rosaline; Riley, Mollie; Wallis, Colin; Chan, Elaine; Abel, Francois; De Lucia, Silvana; Hogrel, Jean‐Yves; Niks, Erik H.; de Groot, Imelda; Servais, Laurent; Straub, Volker; Ricotti, Valeria; Manzur, Adnan; Muntoni, Francesco
• Is Part Of: Muscle & nerve. Volume 65:Issue 1(2022)
• Page Start: 67
• Page End: 74
• Publication Date: 2021-10-27
• Subjects: Duchenne muscular dystrophy -- exon skipping -- forced vital capacity -- genotype -- respiratory function; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.27427
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Introduction/Aims: Mutations amenable to skipping of specific exons have been associated with different motor progression in Duchenne muscular dystrophy (DMD). Less is known about their association with long‐term respiratory function. In this study we investigated the features of respiratory progression in four DMD genotypes relevant in ongoing exon‐skipping therapeutic strategies. Methods: This was a retrospective longitudinal study including DMD children followed by the UK NorthStar Network and international AFM Network centers (May 2003 to October 2020). We included boys amenable to skip exons 44, 45, 51, or 53, who were older than 5 years of age and ambulant at first recorded visit. Subjects who were corticosteroid‐naive or enrolled in interventional clinical trials were excluded. The progression of respiratory function (absolute forced vital capacity [FVC] and calculated as percent predicted [FVC%]) was compared across the four subgroups (skip44, skip45, skip51, skip53). Results: We included 142 boys in the study. Mean (standard deviation) age at first visit was 8.6 (2.5) years. Median follow‐up was 3 (range, 0.3‐8.3) years. In skip45 and skip51, FVC% declined linearly from the first recorded visit. From the age of 9 years, FVC% declined linearly in all genotypes. Skip44 had the slowest (2.7%/year) and skip51 the fastest (5.9%/year) annual FVC% decline. The absolute FVC increased progressively in skip44, skip45, and skip51. In skip53, FVC started declining from 14 years of age. Discussion: The progression of respiratory dysfunction follows different patterns for specific genotype categories. This information is valuable for prognosis and for the evaluation of exon‐skipping therapies.